Galderma announces that the U.S. FDA has approved Sculptra for the correction of fine lines and wrinkles in the cheek area. Sculptra is an injectable poly-L-lactic acid (PLLA-SCA) collagen stimulator that helps stimulate natural collagen production when injected into the cheek area. This, in turn, smooths wrinkles and improves skin quality, such as firmness and glow, with results lasting up to two years.
Bill Andriopoulos, PhD, Galderma’s U.S vice president of medical affairs, spoke out about the FDA approval, calling it a “meaningful milestone for Galderma.” He adds, “With 95% of patients still showing improved skin glow two years after treatment when injected into the cheek region,we recognize how much of an impact biostimulators can have on the aging face. This new indication allows for Sculptra to pave the way as a leader in the PLLA collagen stimulator category, and we are excited to see what the future holds for this innovative product.”
Sabrina Fabi, MD, a double board-certified dermatologist and dermatologic cosmetic surgeon, also addressed FDA approval, commenting: “Sculptra is a foundational treatment that helps smooth wrinkles and offers the added benefit of improved skin quality—helping to firm sagging skin for a more radiant and glowing appearance.”
Fabi adds, “My patients will be extremely pleased that they can now receive Sculptra in the broader cheek region to support collagen growth and to make their skin look more refreshed and rejuvenated.”
